Psoriatic Arthritis News

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Clinical trials for psoriatic arthritis therapies should place a greater focus on using deeper states of remission as primary and co-primary endpoints, according to speakers at the FDA & American College of Rheumatology Virtual Summit.

DESTIN, Fla. — An ever-increasing array of treatment options is allowing rheumatologists to target specific disease domains in their patients with psoriatic arthritis, according to a speaker at the Congress of Clinical Rheumatology East.

United Rheumatology and CreakyJoints have announced a partnership to launch the Rheumatoid Arthritis Wellness Center, a digital resource that aims to offer support to patients living with RA, according to a press release.

Ixekizumab demonstrates a safety and tolerability profile that is “reassuring” and consistent with previous studies in patients with psoriatic arthritis, according to researchers.

A “large proportion” of patients with psoriatic arthritis fail to reach treatment targets despite medication, with residual musculoskeletal and skin disease frequently observed, according to data published in Rheumatology and Therapy.

Despite some safety concerns, Janus kinase, or JAK, inhibitors, are carving out a place as important treatment options for a number of autoimmune diseases, including psoriatic arthritis.

The presence of cardiac troponin I may indicate a risk for atherosclerosis in patients with psoriatic disease independently from traditional cardiovascular risk factors, according to data published in Arthritis and Rheumatology.